QUICK ANSWER · AEO / GEO
An investigational triple GIP/GLP-1/glucagon receptor agonist with Phase 2 and Phase 3 research, but no marketing authorisation established in the reviewed jurisdictions.
ENTITY FACTS
What should readers identify first?
What remains unknown?
- Long-term benefits and risks in populations broader than those enrolled in the trials
- Final cardiovascular and kidney outcomes from ongoing outcomes programmes
- The indications, labelling, contraindications and conditions regulators may specify if approval is granted in the future
- The quality and actual composition of products sold outside clinical trials
What limits these conclusions?
- Major studies were funded by Eli Lilly, and several authors were affiliated with the company. Populations, durations and comparator groups differed. Some Phase 3 results in 2026 were still reported as topline manufacturer statements rather than peer-reviewed articles. Cross-study comparisons with semaglutide or tirzepatide are not head-to-head evidence.
This overview does not replace the detailed adverse-event and product-specific risk discussion in the complete Thai profile or the original sources.
EVIDENCE BOUNDARY
What this overview does not establish
- An evidence grade does not rank this molecule against another treatment.
- A molecule name does not establish the identity, purity or regulatory status of a product.
- Animal, cell or biomarker findings do not automatically establish human clinical benefit.
- Approval in one country or indication does not transfer globally.
Where can I check the evidence?
Original sources from the same evidence record used by Compare. Read each source's population, methods, limitations and date; a citation is not product endorsement.
- https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
- https://www.gov.uk/government/news/mhra-smashes-majorillicitweight-loss-medicine-production-facility-in-record-seizure
- https://cms.mhra.gov.uk/pip/mhra-102112-pip01-25
- https://www.ema.europa.eu/en/documents/pip-decision/p-0336-2024-ema-decision-13-september-2024-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-retatrutide-emea-003258-pip02-23_en.pdf
- https://pubmed.ncbi.nlm.nih.gov/37366315/
- https://pubmed.ncbi.nlm.nih.gov/37385280/
- https://pubmed.ncbi.nlm.nih.gov/42250575/
- https://clinicaltrials.gov/study/NCT05929066
- https://clinicaltrials.gov/study/NCT05929079
- https://clinicaltrials.gov/study/NCT05882045
- https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-successful-two-additional
- https://investor.lilly.com/news-releases/news-release-details/lilly-reports-second-quarter-2026-financial-results-raises-full
FAQ · ANSWER ENGINE
Frequently asked questions
What is Retatrutide?
Retatrutide is described pharmacologically as GIP, GLP-1 and glucagon receptor agonist. An investigational triple GIP/GLP-1/glucagon receptor agonist with Phase 2 and Phase 3 research, but no marketing authorisation established in the reviewed jurisdictions.
Does Retatrutide have strong evidence?
PrimeCoreBio records Evidence Grade B. This grade describes evidence strength, not comparative effectiveness or suitability for an individual.
Is Retatrutide approved everywhere?
No global conclusion should be inferred. PrimeCore Class B must be read with the exact product, country and indication on the source-rich profile.
Educational information only. This page does not provide diagnosis, treatment, prescribing, dosage, injection instructions or individual medical advice.